First, do no harm: risk of secondary cancer after breast cancer treatment

Menée à partir des données 1990-2016 d'une cohorte et des registres américains des cancers portant sur 473 240 patientes ayant survécu à un cancer du sein (durée médiane de suivi : 9,3 ans), cette étude analyse les facteurs associés au risque de sarcome des tissus mous thoraciques lié au traitement par radiothérapie

Résumé en anglais

Breast cancer is the most common malignancy in women worldwide, and the majority of women will survive a diagnosis of early stage disease. As our understanding of the biological subtypes of breast cancer has expanded, treatments for breast cancer have become increasingly tailored, balancing treatment sensitivity, benefits, and individual patient preferences. For this common cancer with substantial long-term survival, health-care providers must weigh therapeutic benefits against short-term and long-term risks.